Patheon is increasing solid dose capabilities at its European sites, with the latest investments being made at its UK facility, Milton Park.
This stand-alone early development centre will now offer automated capsule filling, instrumented tablet compression and tablet coating capabilities as well as increased manufacturing capacity. These upgrades will include DoE and QbD enabled equipment and expansion of time-saving disposable technologies to include tableting.
The Milton Park facility will now have the capability to manufacture supplies for up to Phase IIb studies with seamless transfers to Patheon’s recently upgraded Bourgoin, France, site for later stage clinical trials on compatible, scalable equipment.
Milton Park will also now offer a wider range of dose forms: capsules, oral liquids, suspensions, tablets, microtablets and multiparticulates, as well as controlled-release coating technologies.
This is in addition to established capabilities in high potency API handling, manual filling of up to approximately 10,000 capsules per batch, and the Quick to Clinic鈩� service offering for rapid results in early stage projects.
"This latest investment in Milton Park will enhance our flexible early development offerings with a wider range of dosage forms, technologies and capacity, all from one purpose-built facility," said Jon Sutch, manager of formulation and clinical trials manufacture, based at Patheon’s Milton Park facility.
"It positions Patheon as Europe’s strategic partner of choice for oral dose early development."